Thus, tuning the levels of T-bet expression in ILCs could potentially represent a tool to optimise immune responses, allowing a selective regulation of protective vs. pathological ILC responses, which could be relevant for the treatment of IBD and other ILC-mediated conditions. The gene discussed is CCL27; the disease is inflammatory bowel disease.